GLPTree
Calculators Articles About Start projecting

Calculator

Plateau Predictor

Estimate when weight loss is likely to slow or plateau on your GLP-1 based on published trial data. SURMOUNT-1 shows tirzepatide plateauing around weeks 60–72; STEP-1 shows semaglutide plateauing around week 60.

Advertisement

Your therapy details

Higher doses reach plateau later and with greater total loss.

E.g., if you started at 220 lb and now weigh 209 lb, that's 5%.

Plateau estimate

~48 more weeks to plateau

Based on trial data for your medication and dose, plateau is likely around week 60.

Plateau at week
60
Total loss (low est.)
11%
Total loss (high est.)
16%

Tips for breaking through a plateau

  • 1. Increase protein intake. Aim for 1.2–1.6 g per kg of body weight to preserve lean mass and maintain satiety.
  • 2. Add resistance training. Muscle mass increases metabolic rate and counters GLP-1-induced muscle loss risk.
  • 3. Discuss dose escalation with your prescriber. If you are not at the maximum dose, escalating may restart loss — but this requires clinical judgment.
  • 4. Re-evaluate sleep and stress. Cortisol and sleep deprivation can stall weight loss independent of medication.
  • 5. Consider a medication switch. If on a GLP-1 agonist, discuss tirzepatide (GLP-1 + GIP) with your prescriber — SURMOUNT-1 showed superior outcomes vs semaglutide-equivalent populations.
Educational tool only. Not medical advice. Consult your prescriber before making decisions about medications, calorie targets, or weight goals. Individual variation in GLP-1 response is very high — some patients continue losing beyond typical trial plateau points, while others plateau earlier. Trial averages (SURMOUNT-1, STEP-1) reflect population means, not individual guarantees.
Advertisement
How plateau timing is estimated

This calculator uses published trial data to model the plateau point — the week at which mean weight loss in trial participants largely stabilized:

  • Tirzepatide (Zepbound/Mounjaro max dose — SURMOUNT-1): Mean loss curve plateaued between weeks 60–72 at approximately 22.5% body weight loss at 15 mg.
  • Tirzepatide mid dose (10 mg): Plateau around weeks 56–68 at approximately 19.5%.
  • Tirzepatide low dose (5 mg): Plateau around weeks 52–60 at approximately 15%.
  • Semaglutide 2.4 mg (Wegovy — STEP-1): Plateau around week 60 at approximately 14.9% mean loss.
  • Ozempic / compounded semaglutide (lower doses): Plateau around weeks 40–52 at approximately 5–9% (T2D population; non-diabetic may lose more).
  • Compounded tirzepatide: Modeled similarly to branded tirzepatide by dose level, as compounding replicates the same molecule.

Your current week and percent lost are plotted against the trial curve to estimate remaining weeks and additional expected loss.

What causes a GLP-1 plateau?

GLP-1 weight loss plateaus occur for several reasons:

  • Metabolic adaptation: As body weight drops, TDEE decreases, reducing the calorie deficit.
  • Lean mass loss: GLP-1s can cause some muscle loss, which lowers resting metabolic rate.
  • Medication ceiling: GLP-1 receptors reach saturation at higher doses; additional drug above the ceiling has diminishing returns.
  • Appetite accommodation: Some patients experience attenuation of the appetite-suppressive effect over time.

Read more: GLP-1 Weight Loss Plateaus — What the Science Says

Advertisement

Sources